HIGHBuilt-in & outside partyProduct / Revenue mix
DEXTENZA
“10-K Item 1A: 'we expect to continue to generate revenue from sales of DEXTENZA... we expect to continue to incur significant expenses and operating losses'”
OCUL · Concentration risk · 10-K extracted
Ocular Therapeutix (OCUL) concentration risks
Updated
The most significant concentration Ocular Therapeutix discloses is DEXTENZA, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Ocular Therapeutix’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH2
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHBuilt-in & outside partyPipeline
AXPAXLI
“10-K Item 1A: 'our lead product candidate AXPAXLI... conduct extensive clinical trials to demonstrate the safety and efficacy'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's concentration profile is a dual high-share dependency that spans its commercial product and lead pipeline candidate. DEXTENZA is the company's primary commercial product, and the filing indicates that it is expected to continue generating revenue while the company also continues to incur significant expenses and operating losses. This commercial dependency is high-share by disclosed size and mixed in character: it reflects both a current revenue stream and ongoing cash consumption, making the product simultaneously the company's primary source of income and a driver of burn. The lead pipeline candidate AXPAXLI carries a parallel high-share dependency at the clinical stage, requiring extensive trials to demonstrate safety and efficacy before it could contribute to revenue. Its mixed character reflects the balance between its strategic importance as a potential commercial successor and the binary clinical execution risk inherent in late-stage development. A setback in the AXPAXLI program would leave the company more heavily reliant on DEXTENZA revenues for an extended period. Together, the two exposures describe a company in a transition phase: one commercial product generating revenue while carrying operating losses, and one clinical candidate whose advancement is expected to define the medium-term growth profile. There is no disclosed geographic or supplier concentration. The concentration profile is entirely product and pipeline driven, and investors should track DEXTENZA revenue trends and AXPAXLI clinical milestones as the two primary variables governing near-term financial outcomes.
For the engine’s reasoning on OCUL’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| OCUL● | Ocular Therapeutix, Inc. | 2 | 0 | 0 | 2 |
| ACLX | Arcellx, Inc. | 1 | 1 | 0 | 2 |
| AGIO | Agios Pharmaceuticals, Inc. | 1 | 0 | 0 | 1 |
| ALMS | Alumis Inc. | 1 | 0 | 0 | 1 |
| ADMA | ADMA Biologics Inc | 0 | 1 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.